(Q43893454)

27 November 2017

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid (English)

1 reference

primary biliary cholangitis

27 November 2017

0 references

author name string

Angulo P

1

1 reference

27 November 2017

Lindor KD

2

1 reference

27 November 2017

Therneau TM

3

1 reference

27 November 2017

Jorgensen RA

4

1 reference

27 November 2017

Malinchoc M

5

1 reference

27 November 2017

Kamath PS

6

1 reference

27 November 2017

Dickson ER

7

1 reference

27 November 2017

1 April 1999

1 reference

27 November 2017

1 reference

27 November 2017

19

1 reference

27 November 2017

2

1 reference

27 November 2017

115-121

1 reference

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

27 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00020.X

The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00020.X

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00020.X

Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00020.X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.1999.TB00020.X

10.1111/J.1478-3231.1999.TB00020.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference